388 related articles for article (PubMed ID: 23545925)
41. Biologic therapy in psoriasis: perspectives on associated risks and patient management.
Papp KA; Dekoven J; Parsons L; Pirzada S; Robern M; Robertson L; Tan JK
J Cutan Med Surg; 2012; 16(3):153-68. PubMed ID: 22713438
[TBL] [Abstract][Full Text] [Related]
42. Long-term management of erythrodermic psoriasis with anti-TNF agents.
Romero-Maté A; García-Donoso C; Martinez-Morán C; Hernández-Núñez A; Borbujo J
Dermatol Online J; 2010 Jun; 16(6):15. PubMed ID: 20579470
[TBL] [Abstract][Full Text] [Related]
43. Infliximab-induced psoriasis in treatment of Crohn's disease-associated ankylosing spondylitis: case report and review of 142 cases.
Famenini S; Wu JJ
J Drugs Dermatol; 2013 Aug; 12(8):939-43. PubMed ID: 23986169
[TBL] [Abstract][Full Text] [Related]
44. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection.
Carroll MB; Bond MI
Semin Arthritis Rheum; 2008 Dec; 38(3):208-17. PubMed ID: 18221983
[TBL] [Abstract][Full Text] [Related]
45. Tumor necrosis factor inhibitors in psoriasis: an update.
Kerdel FA; Strober BE
Semin Cutan Med Surg; 2014 Mar; 33(2 Suppl 2):S31-6. PubMed ID: 24979543
[TBL] [Abstract][Full Text] [Related]
46. Use of anti-tumor necrosis factor-α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan.
Cho YT; Chen CH; Chiu HY; Tsai TF
J Dermatol; 2012 Mar; 39(3):269-73. PubMed ID: 22077677
[TBL] [Abstract][Full Text] [Related]
47. Detection and management of latent tuberculosis infections before biologic therapy for psoriasis.
Amerio P; Amoruso G; Bardazzi F; Campanati A; Cassano N; Conti A; Gisondi P; Guarneri C; Mazzotta A; Piaserico S; Prestinari F; Prignano F; Zane C; de Simone C
J Dermatolog Treat; 2013 Aug; 24(4):305-11. PubMed ID: 22208431
[TBL] [Abstract][Full Text] [Related]
48. [Biological treatment of psoriasis and psoriatic arthritis].
Kragballe K; Deleuran B
Ugeskr Laeger; 2008 Jun; 170(24):2148-50. PubMed ID: 18565300
[TBL] [Abstract][Full Text] [Related]
49. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors.
Deng A; Harvey V; Sina B; Strobel D; Badros A; Junkins-Hopkins JM; Samuels A; Oghilikhan M; Gaspari A
Arch Dermatol; 2006 Feb; 142(2):198-202. PubMed ID: 16490847
[TBL] [Abstract][Full Text] [Related]
50. [Infectious risk].
Calabuig E; Salavert M
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():14-22. PubMed ID: 19080987
[TBL] [Abstract][Full Text] [Related]
51. Erythema multiforme during anti-tumor necrosis factor treatment for plaque psoriasis.
Ahdout J; Haley JC; Chiu MW
J Am Acad Dermatol; 2010 May; 62(5):874-9. PubMed ID: 19913942
[TBL] [Abstract][Full Text] [Related]
52. [Biological treatment of ankylosing spondylitis].
Freiesleben S; Schou M
Ugeskr Laeger; 2008 Jun; 170(24):2140-5. PubMed ID: 18565298
[TBL] [Abstract][Full Text] [Related]
53. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study.
Fouache D; Goëb V; Massy-Guillemant N; Avenel G; Bacquet-Deschryver H; Kozyreff-Meurice M; Ménard JF; Muraine M; Savoye G; Le Loët X; Tharasse C; Vittecoq O
Rheumatology (Oxford); 2009 Jul; 48(7):761-4. PubMed ID: 19395543
[TBL] [Abstract][Full Text] [Related]
54. Onychomycosis in patients of nail psoriasis on biologic therapy: a randomized, prospective open label study comparing Etanercept, Infliximab and Adalimumab.
Al-Mutairi N; Nour T; Al-Rqobah D
Expert Opin Biol Ther; 2013 May; 13(5):625-9. PubMed ID: 23527597
[TBL] [Abstract][Full Text] [Related]
55. Anti-tumor necrosis factor alpha therapy in psoriatic arthritis and psoriasis.
Girolomoni G; Abeni D
Arch Dermatol; 2001 Jun; 137(6):784-5. PubMed ID: 11405771
[No Abstract] [Full Text] [Related]
56. [Adverse reactions during biological therapy for psoriasis: results of a survey of the Spanish Psoriasis Group].
Sánchez-Regaña M; Dilmé E; Puig L; Bordas X; Carrascosa JM; Ferran M; Herranz P; García-Bustinduy M; López Estebaranz JL; Alsina M; Rodríguez MA; Ribera M; Fernández-López E; Moreno JC; Belinchón Romero I; Vidal D;
Actas Dermosifiliogr; 2010 Mar; 101(2):156-63. PubMed ID: 20223158
[TBL] [Abstract][Full Text] [Related]
57. Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis.
Krueger G; Callis K
Arch Dermatol; 2004 Feb; 140(2):218-25. PubMed ID: 14967799
[TBL] [Abstract][Full Text] [Related]
58. Paradoxical worsening of psoriasis when switching from etanercept to adalimumab: a case series.
Bhutani T; Koo J
J Dermatolog Treat; 2011 Apr; 22(2):75-8. PubMed ID: 20524874
[TBL] [Abstract][Full Text] [Related]
59. Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?
Langley RG
J Eur Acad Dermatol Venereol; 2012 Mar; 26 Suppl 2():21-9. PubMed ID: 22356632
[TBL] [Abstract][Full Text] [Related]
60. Biologicals in the treatment of psoriasis.
Boker A; Kimball AB; Rolz-Cruz G
Curr Opin Investig Drugs; 2007 Nov; 8(11):939-46. PubMed ID: 17979028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
